Efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan

Abstract The clinical efficacy of ticagrelor versus clopidogrel has not been replicated in East Asian populations. The pronounced bleeding risk with ticagrelor was of concern given the increased bleeding tendency in Asian populations. This study evaluated efficacy and safety of ticagrelor versus clo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chih-Kuo Lee, Tzung-Dau Wang, Hsiao-Ting Juang, Shu-Chen Chang, Heng-Yu Pan, Donna Shu-Han Lin, Chee-Jen Chang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/169d03786fa845b39a8e5826678efec5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:169d03786fa845b39a8e5826678efec5
record_format	dspace
spelling	oai:doaj.org-article:169d03786fa845b39a8e5826678efec52021-12-02T18:34:13ZEfficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan10.1038/s41598-021-93712-92045-2322https://doaj.org/article/169d03786fa845b39a8e5826678efec52021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93712-9https://doaj.org/toc/2045-2322Abstract The clinical efficacy of ticagrelor versus clopidogrel has not been replicated in East Asian populations. The pronounced bleeding risk with ticagrelor was of concern given the increased bleeding tendency in Asian populations. This study evaluated efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction (NSTEMI) in the entire Taiwan. We used the Taiwan National Health Insurance Research Database to identify 6203 patients aged ≥ 20 years with NSTEMI hospitalization and prescription of dual antiplatelets at discharge between January 2014 and December 2014. Cohorts of ticagrelor and clopidogrel were matched 1:1 based on propensity score matching to balance baseline covariates. The primary composite efficacy endpoints included death from any cause, non-fatal myocardial infarction, and non-fatal stroke. The secondary efficacy endpoints were the individual components. The primary safety endpoint was major bleeding requiring hospitalization. The incidence of primary efficacy endpoint was 20.3% in the ticagrelor users and 20.7% in the clopidogrel users (adjusted HR 0.94; 95% CI 0.73–1.22), with the median (interquartile range, IQR) follow-up period of 5.2 (2.3–8.5) months. The incidence of primary safety endpoint was 2.3% in the ticagrelor users and 3.2% in the clopidogrel users (adjusted HR 0.67; 95% CI 0.33–1.35). Regarding the secondary efficacy endpoint, patients treated with ticagrelor had significantly lower incidence of stroke (adjusted HR 0.44; 95% CI 0.21–0.94; p = 0.033). In this nationwide Taiwanese cohort of NSTEMI, treatment with ticagrelor after discharge, as compared to clopidogrel, had similar rates of ischemic composite events and major bleeding. Nevertheless, the median follow-up time was only 5.2 months, and the reduced stroke events with ticagrelor compared to clopidogrel needs further verification.Chih-Kuo LeeTzung-Dau WangHsiao-Ting JuangShu-Chen ChangHeng-Yu PanDonna Shu-Han LinChee-Jen ChangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chih-Kuo Lee Tzung-Dau Wang Hsiao-Ting Juang Shu-Chen Chang Heng-Yu Pan Donna Shu-Han Lin Chee-Jen Chang Efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan
description	Abstract The clinical efficacy of ticagrelor versus clopidogrel has not been replicated in East Asian populations. The pronounced bleeding risk with ticagrelor was of concern given the increased bleeding tendency in Asian populations. This study evaluated efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction (NSTEMI) in the entire Taiwan. We used the Taiwan National Health Insurance Research Database to identify 6203 patients aged ≥ 20 years with NSTEMI hospitalization and prescription of dual antiplatelets at discharge between January 2014 and December 2014. Cohorts of ticagrelor and clopidogrel were matched 1:1 based on propensity score matching to balance baseline covariates. The primary composite efficacy endpoints included death from any cause, non-fatal myocardial infarction, and non-fatal stroke. The secondary efficacy endpoints were the individual components. The primary safety endpoint was major bleeding requiring hospitalization. The incidence of primary efficacy endpoint was 20.3% in the ticagrelor users and 20.7% in the clopidogrel users (adjusted HR 0.94; 95% CI 0.73–1.22), with the median (interquartile range, IQR) follow-up period of 5.2 (2.3–8.5) months. The incidence of primary safety endpoint was 2.3% in the ticagrelor users and 3.2% in the clopidogrel users (adjusted HR 0.67; 95% CI 0.33–1.35). Regarding the secondary efficacy endpoint, patients treated with ticagrelor had significantly lower incidence of stroke (adjusted HR 0.44; 95% CI 0.21–0.94; p = 0.033). In this nationwide Taiwanese cohort of NSTEMI, treatment with ticagrelor after discharge, as compared to clopidogrel, had similar rates of ischemic composite events and major bleeding. Nevertheless, the median follow-up time was only 5.2 months, and the reduced stroke events with ticagrelor compared to clopidogrel needs further verification.
format	article
author	Chih-Kuo Lee Tzung-Dau Wang Hsiao-Ting Juang Shu-Chen Chang Heng-Yu Pan Donna Shu-Han Lin Chee-Jen Chang
author_facet	Chih-Kuo Lee Tzung-Dau Wang Hsiao-Ting Juang Shu-Chen Chang Heng-Yu Pan Donna Shu-Han Lin Chee-Jen Chang
author_sort	Chih-Kuo Lee
title	Efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan
title_short	Efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan
title_full	Efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan
title_fullStr	Efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan
title_full_unstemmed	Efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan
title_sort	efficacy and safety of ticagrelor versus clopidogrel in patients with non-st-elevation myocardial infarction in taiwan
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/169d03786fa845b39a8e5826678efec5
work_keys_str_mv	AT chihkuolee efficacyandsafetyofticagrelorversusclopidogrelinpatientswithnonstelevationmyocardialinfarctionintaiwan AT tzungdauwang efficacyandsafetyofticagrelorversusclopidogrelinpatientswithnonstelevationmyocardialinfarctionintaiwan AT hsiaotingjuang efficacyandsafetyofticagrelorversusclopidogrelinpatientswithnonstelevationmyocardialinfarctionintaiwan AT shuchenchang efficacyandsafetyofticagrelorversusclopidogrelinpatientswithnonstelevationmyocardialinfarctionintaiwan AT hengyupan efficacyandsafetyofticagrelorversusclopidogrelinpatientswithnonstelevationmyocardialinfarctionintaiwan AT donnashuhanlin efficacyandsafetyofticagrelorversusclopidogrelinpatientswithnonstelevationmyocardialinfarctionintaiwan AT cheejenchang efficacyandsafetyofticagrelorversusclopidogrelinpatientswithnonstelevationmyocardialinfarctionintaiwan
_version_	1718377845435138048

Efficacy and safety of ticagrelor versus clopidogrel in patients with non-ST-elevation myocardial infarction in Taiwan

Ejemplares similares